DZ2222A1 - Dihydrates de mésylate de 5-(2-(4-(1,2-benzisothiazole-3-al)-1-pipérazinyl)éthyl)-6-chloro-1,3-dihydro-2h-indole-2-one. - Google Patents

Dihydrates de mésylate de 5-(2-(4-(1,2-benzisothiazole-3-al)-1-pipérazinyl)éthyl)-6-chloro-1,3-dihydro-2h-indole-2-one.

Info

Publication number
DZ2222A1
DZ2222A1 DZ970069A DZ970069A DZ2222A1 DZ 2222 A1 DZ2222 A1 DZ 2222A1 DZ 970069 A DZ970069 A DZ 970069A DZ 970069 A DZ970069 A DZ 970069A DZ 2222 A1 DZ2222 A1 DZ 2222A1
Authority
DZ
Algeria
Prior art keywords
dihydrates
benzisothiazole
piperazinyl
indole
dihydro
Prior art date
Application number
DZ970069A
Other languages
English (en)
French (fr)
Inventor
Frank Robert Busch
Carol Anne Rose
Russell James Shine
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DZ2222A1 publication Critical patent/DZ2222A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
DZ970069A 1996-05-07 1997-05-06 Dihydrates de mésylate de 5-(2-(4-(1,2-benzisothiazole-3-al)-1-pipérazinyl)éthyl)-6-chloro-1,3-dihydro-2h-indole-2-one. DZ2222A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1675796P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
DZ2222A1 true DZ2222A1 (fr) 2002-12-03

Family

ID=21778804

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ970069A DZ2222A1 (fr) 1996-05-07 1997-05-06 Dihydrates de mésylate de 5-(2-(4-(1,2-benzisothiazole-3-al)-1-pipérazinyl)éthyl)-6-chloro-1,3-dihydro-2h-indole-2-one.

Country Status (40)

Country Link
US (1) US6245765B1 (forum.php)
EP (1) EP0918772B1 (forum.php)
JP (1) JP3494659B2 (forum.php)
KR (1) KR100333215B1 (forum.php)
CN (1) CN1091769C (forum.php)
AP (1) AP765A (forum.php)
AR (1) AR007004A1 (forum.php)
AT (1) ATE278689T1 (forum.php)
AU (1) AU731267B2 (forum.php)
BG (1) BG63544B1 (forum.php)
BR (1) BR9709889A (forum.php)
CA (1) CA2252898C (forum.php)
CO (1) CO4940466A1 (forum.php)
CZ (1) CZ289215B6 (forum.php)
DE (1) DE69731094T2 (forum.php)
DK (1) DK0918772T3 (forum.php)
DZ (1) DZ2222A1 (forum.php)
EA (1) EA001190B1 (forum.php)
EG (1) EG24076A (forum.php)
ES (1) ES2229342T3 (forum.php)
GT (1) GT199700052A (forum.php)
HR (1) HRP970236B1 (forum.php)
ID (1) ID16867A (forum.php)
IL (1) IL126591A (forum.php)
IS (1) IS2080B (forum.php)
MA (1) MA24171A1 (forum.php)
MY (1) MY119997A (forum.php)
NO (1) NO312514B1 (forum.php)
NZ (1) NZ332218A (forum.php)
OA (1) OA10909A (forum.php)
PL (1) PL188330B1 (forum.php)
PT (1) PT918772E (forum.php)
SI (1) SI0918772T1 (forum.php)
SK (1) SK282837B6 (forum.php)
TN (1) TNSN97074A1 (forum.php)
TR (1) TR199802240T2 (forum.php)
TW (1) TW491847B (forum.php)
UA (1) UA46840C2 (forum.php)
WO (1) WO1997042191A1 (forum.php)
ZA (1) ZA973876B (forum.php)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
EP1698338B1 (en) * 2000-06-02 2008-04-09 Pfizer Products Inc. S-methyl-dihydro-ziprasidone for the treatment of schizophrenia
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
WO2004100992A2 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
EP1530570A2 (en) * 2003-06-03 2005-05-18 Teva Pharmaceutical Industries Limited CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
US7667037B2 (en) 2003-10-24 2010-02-23 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
BRPI0510942A (pt) * 2004-05-11 2007-07-17 Pfizer Prod Inc combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
WO2006055603A2 (en) * 2004-11-16 2006-05-26 Elan Pharma International Ltd. Injectable nanoparticulate olanzapine formulations
WO2006086779A1 (en) * 2005-02-11 2006-08-17 Teva Pharmaceutical Industries Ltd. Amorphous ziprasidone mesylate
WO2006086787A1 (en) * 2005-02-11 2006-08-17 Teva Pharmaceutical Industries Ltd. Process of preparing ziprasidone mesylate
WO2006096462A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
WO2006098834A2 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
US20060270685A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Anhydrous ziprasidone mesylate and a process for its preparation
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
WO2008143960A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
JP2011526881A (ja) * 2008-06-25 2011-10-20 ファイザー・インク ジアリール化合物およびそれらの使用
JP5893616B2 (ja) * 2010-10-18 2016-03-23 大日本住友製薬株式会社 注射用徐放性製剤
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
AU730856C (en) 1996-05-07 2001-11-15 Pfizer Inc. Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol- 3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)- indol-2-one(=ziprasidone),it's preparation and it's use as dopamine D2 antagonist

Also Published As

Publication number Publication date
NO312514B1 (no) 2002-05-21
CA2252898A1 (en) 1997-11-13
TW491847B (en) 2002-06-21
US6245765B1 (en) 2001-06-12
GT199700052A (es) 2001-08-29
JP3494659B2 (ja) 2004-02-09
KR20000010824A (ko) 2000-02-25
CZ349398A3 (cs) 1999-09-15
BG63544B1 (bg) 2002-04-30
AP9700976A0 (en) 1997-07-31
ID16867A (id) 1997-11-20
NO985194L (no) 1998-11-06
BR9709889A (pt) 1999-08-10
UA46840C2 (uk) 2002-06-17
DE69731094T2 (de) 2006-02-23
AU2174797A (en) 1997-11-26
AR007004A1 (es) 1999-10-13
TNSN97074A1 (fr) 2005-03-15
DK0918772T3 (da) 2005-01-10
CZ289215B6 (cs) 2001-12-12
HRP970236A2 (en) 1998-06-30
IL126591A (en) 2001-11-25
AU731267B2 (en) 2001-03-29
IS2080B (is) 2006-02-15
EA001190B1 (ru) 2000-12-25
DE69731094D1 (de) 2004-11-11
HK1017892A1 (en) 1999-12-03
JPH11509867A (ja) 1999-08-31
CO4940466A1 (es) 2000-07-24
SK282837B6 (sk) 2002-12-03
SK150898A3 (en) 2000-02-14
PL329884A1 (en) 1999-04-12
ZA973876B (en) 1998-11-06
TR199802240T2 (forum.php) 1999-02-22
EA199800912A1 (ru) 1999-04-29
PT918772E (pt) 2004-12-31
ATE278689T1 (de) 2004-10-15
CA2252898C (en) 2003-04-08
OA10909A (en) 2001-10-26
CN1091769C (zh) 2002-10-02
BG102892A (en) 1999-09-30
MY119997A (en) 2005-08-30
PL188330B1 (pl) 2005-01-31
SI0918772T1 (en) 2005-02-28
EP0918772B1 (en) 2004-10-06
NO985194D0 (no) 1998-11-06
AP765A (en) 1999-09-17
KR100333215B1 (ko) 2002-06-20
WO1997042191A1 (en) 1997-11-13
EP0918772A1 (en) 1999-06-02
ES2229342T3 (es) 2005-04-16
HRP970236B1 (en) 2002-12-31
MA24171A1 (fr) 1997-12-31
IS4874A (is) 1998-10-20
CN1216991A (zh) 1999-05-19
EG24076A (en) 2008-05-11
IL126591A0 (en) 1999-08-17
NZ332218A (en) 2005-02-25

Similar Documents

Publication Publication Date Title
DZ2222A1 (fr) Dihydrates de mésylate de 5-(2-(4-(1,2-benzisothiazole-3-al)-1-pipérazinyl)éthyl)-6-chloro-1,3-dihydro-2h-indole-2-one.
ID17504A (id) Mesilat trihidrat 5-(2-(4-1,2-benzisotiazol-3-il)-1-piperazinil)-etil)-6-kloro-1,3-dihidro-2h-indol-2-on
FI933804A0 (fi) Monohydrat av 5-(2-(4-(1,2-bensisotiazol-3-yl)-1-piperazinyl)etyl-6-klor-1,3-dihydro-2h-indol-2-onkhydroklorid
MA26601A1 (fr) Derives 2-(purin-9yl)-tetrahydrofurant-3,4-diol .
TR199700092A2 (tr) Yeni, sübstitüe edilmis oksazolidinonlar.
TR199800444A3 (tr) Hipolipidemik 1,4-benzotiazepin-1,1-diyoksitler.
DE69226449D1 (de) 2-(2,6-difluorphenyl)-4-(2-ethoxy-4-tert-butylphenyl)-2-axazoline
ATE226212T1 (de) 2-(purin-9-)-tetrahydrofuran-3,4-diol-derivate
SV1996000005A (es) Quinazolinonas bisustituidas en 2,8
IT1320120B1 (it) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-0-tolil-piridin-3-il) -isobutirrammide.
BR9609849B1 (pt) derivados de 2-(4-substituìda) -benzilamino-2-metila-propanamida.
FR14C0044I2 (fr) Derives de 3-(2-oxo- 1,3']bipyrrolidinyl-3-ylidenemethyl)-cephemes
ID28874A (id) Inhibitor fosfodiesterase 4 turunan ftalazina.
DZ2583A1 (fr) Dérivés de 2-(4-aryl-ou hétéroaryl-pipérazine-1-ylméthyl)-1h-indole.
ZA972973B (en) Substituted [2-(1-piperazinyl)ethoxy]methyl compounds.
DZ2642A1 (fr) Hydrohalogénures 1'-Ä4-Ä1-(fluorphényl)-1h-indole-3ylÜ-1-butylÜ-spiroÄisobenzufuran-1(3h),4'-pipéridineÜ.
ATE430600T1 (de) 2-(3,5-bis-trifluormethyl-phenyl)-n- 6-(1,1-dio o-1.lambda.6-thiomorpholin-4-yl)-4-(2-methyl- oder 4-fluor-2-methyl-substituiertes)phenyl-pyridin- - yl -n-methyl-isobutyramid
FI912888L (fi) 2-(aminoalkyl)-5-(arylalkyl)-1,3 -dioxanderivat, deras framstaellning och terapeutiska tillaempning.
DE59906902D1 (de) Herbizide 3-(benzo(ox/thi)azol-7-yl)-1h-pyrimidin-2,4-dione
AP9901696A0 (en) Composition comprising 5-(4-(2-(N-methyl-N-2-pyridyl)amino) ehtoxy benzyl)thiazolidine-2,4-dione
FI923723A0 (fi) 4-(4-(4-4-hydroxifenyl)-1 -piperazinyl)fenyl)-5-metyl-3h-1,2,4-triazol-3-on derivat.
ATE525362T1 (de) 2-(3-(4-(2-t-butyl-6-trifluormethylpyrimidin-4-
DE69630123D1 (en) Optische spaltung von 1-azabicylo(2.2.2)octan-3-amin,2-(diphenylmethyl)-n-((2-methoxy-5-(1-methylethyl)phenyl)methyl)
BR9805393B1 (pt) processo para preparar 2-(metiltio)-5-(trifluormetil)-1,3,4-tiadiazol usando metil ditiocarbazinato.
FI913654L (fi) 2-(9-fluorenonyl)-karbapenem.